Previous Close | 154.81 |
Open | 154.46 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's Range | 145.25 - 157.75 |
52 Week Range | 19.31 - 189.26 |
Volume | 15,351,555 |
Avg. Volume | 19,876,618 |
Market Cap | 62.285B |
Beta (5Y Monthly) | 1.50 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.96 |
Earnings Date | May 05, 2021 - May 10, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 168.92 |
Novavax CEO Stanley Erck joined Yahoo Finance Live to discuss the company's COVID-19 vaccine trial progress and his business outlook for the company.
Johnson & Johnson’s single-shot coronavirus vaccine wins FDA approval. Yahoo FInance’s Anjalee Khemlani breaks down the details.
The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna COVID-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper. Fauci said that delaying a second dose to inoculate more Americans creates risks. He warned that shifting to a single-dose strategy for the vaccines could leave people less protected, enable variants to spread and possibly boost skepticism among Americans already hesitant to get the shots.